Market Overview

UPDATE: Canaccord Genuity Raises PT on NuVasive on Multiple Positive Factors

Related NUVA
NuVasive Gets Unfavorable Trademark Verdict - Analyst Blog
NuVasive Announces $30M Unfavorable Jury Verdict for Use of Trade-Name 'NeuroVision' 8-K

In a report published Wednesday, Canaccord Genuity analyst William J. Plovanic reiterated a Buy rating on NuVasive (NASDAQ: NUVA), and raised the price target from $24.50 to $29.00.

In the report, Canaccord Genuity noted, “We reiterate our BUY rating and are positioning NuVasive as our top new money pick. We believe the margin expansion story is tangible and expect investors to focus on 2015 margins and earnings given a significant portion of the IP royalty payments to Medtronic cease at that point. Furthermore, we believe the recent acquisition of a manufacturer and the initiation of product introduction in Japan offer additional margin expansion opportunities. All in, we believe operating margins could expand by ~480 basis points over the next two years.”

NuVasive closed on Tuesday at $22.34.

Posted-In: Canaccord Genuity William J. PlovanicAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (NUVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free